All conditions

Asthma

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

3390
Trials on record
240
Recruiting now
4
Australian sites
28
Phase 3 trials
23
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Asthma →

Get alerts when Asthma trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Asthma

Asthma is a condition that affects the airways — the tubes that carry air in and out of your lungs. In people with asthma, these airways can become inflamed, swollen, and narrowed, which makes it harder to breathe. This can cause symptoms like wheezing, coughing, a tight feeling in the chest, and shortness of breath. Symptoms can come and go, and certain things — called triggers — can make them worse. Common triggers include dust mites, pollen, cigarette smoke, exercise, cold air, and respiratory infections like colds.

Asthma is very common in Australia. In fact, Australia has one of the highest rates of asthma in the world, with around 2.8 million Australians living with the condition. It can affect people of all ages, including children, adults, and older people. Some people find their symptoms improve as they get older, while others manage the condition throughout their lives. You are certainly not alone in receiving this diagnosis.

Treatment for asthma generally focuses on two main goals: relieving symptoms when they happen, and reducing the frequency and severity of those symptoms over time. This typically involves inhaled medications — often delivered through a device called a puffer or inhaler. Some medications work quickly to open up the airways during symptoms, while others are taken regularly to help keep inflammation under control. Doctors may also work with patients to identify and avoid personal triggers. A written Asthma Action Plan is a tool commonly used in Australia to help people know what to do in different situations. A healthcare professional is the best person to talk to about what options are suitable for your individual circumstances.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Asthma in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Asthma

23 medicines listed on the PBS for Asthma. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 23 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Beclometasone Qvar 50 Autohaler, Qvar 100 Autohaler Asthma AU$10.96 Restricted benefit
beclometasone + formoterol Fostair 200/6, Fostair Asthma AU$22.33 Streamlined authority
Budesonide + formoterol Symbicort Rapihaler 200/6, Symbicort Rapihaler 100/3, DuoResp Spiromax +4 more Asthma AU$11.17 Streamlined authority
fluticasone furoate + vilanterol Breo Ellipta 200/25, Breo Ellipta 100/25 Asthma AU$39.79 Streamlined authority
fluticasone propionate Flixotide Junior Asthma AU$6.89 Streamlined authority
fluticasone propionate + formoterol flutiform 125/5, flutiform 250/10, flutiform 50/5 Asthma AU$24.01 Streamlined authority
fluticasone propionate + salmeterol Seretide Accuhaler 500/50, Seretide Accuhaler 250/50, Seretide MDI 250/25 +3 more Asthma AU$27.07 Streamlined authority
Formoterol Foradile, Oxis Turbuhaler Asthma AU$10.2 Restricted benefit
indacaterol + mometasone Atectura Breezhaler Asthma AU$22.8 Streamlined authority
Ipratropium Atrovent, Atrovent Adult Asthma AU$6.41 Restricted benefit
Montelukast Montelukast Sandoz 5, Montelukast Sandoz 4 Asthma AU$4 Streamlined authority
Salbutamol Ventolin Nebules, Salbutamol (as sulfate) (Accord, UK), Salbutamol Cipla Asthma AU$2.98 Restricted benefit
Salmeterol Serevent Accuhaler Asthma AU$15.8 Restricted benefit
Benralizumab Fasenra Pen asthma Uncontrolled severe AU$3145.45 Authority required
Dupilumab Dupixent asthma Uncontrolled severe AU$1609.86 Authority required
Mepolizumab Nucala asthma Uncontrolled severe AU$1556.1 Authority required
Omalizumab Omlyclo, Xolair asthma Uncontrolled severe AU$102.99 Authority required
Tezepelumab Tezspire asthma Uncontrolled severe AU$1671.78 Authority required
beclometasone + formoterol + glycopyrronium Trimbow asthma Severe AU$57.05 Streamlined authority
fluticasone furoate + umeclidinium + vilanterol Trelegy Ellipta 200/62.5/25 asthma Severe AU$70.31 Streamlined authority
indacaterol + glycopyrronium + mometasone Enerzair Breezhaler asthma Severe AU$55.58 Streamlined authority
Tiotropium Spiriva Respimat asthma Severe AU$28.82 Streamlined authority
Omalizumab Omlyclo, Xolair allergic asthma severe AU$102.99 Authority required
Budesonide Pulmicort Respules asthma Severe chronic AU$70 Streamlined authority
Budesonide + formoterol Symbicort Rapihaler 100/3, DuoResp Spiromax, Rilast TURBUHALER 200/6 +1 more asthma Mild AU$11.17 Streamlined authority

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Asthma currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Asthma.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Asthma by country. Australia is highlighted.

Showing the top 10 of 59 countries with trial sites.

Clinical trials for Asthma

Showing 244 of 244 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00231114 · Boston Scientific Corporation Not Applicable · 7 countries Completed
Completed Not Applicable Est. completion 1 August 2008
🇦🇺 AU🇧🇷 BR🇨🇦 CA🇩🇰 DK🇳🇱 NL🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You are between 18 and 65 years old. - You have asthma and are currently taking two types of regular medication: an inhaled corticosteroid (a preventer inhaler) AND a long-acting bronchodilator (a long-acting reliever inhaler). - Your lung function, measured by a breathing test b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT01691521 · GlaxoSmithKline Phase 3 · 16 countries Completed
Completed Phase 3 Est. completion 1 January 2014
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇱 CL🇫🇷 FR🇩🇪 DE🇮🇹 IT +8 more

**Who might be able to join this trial:** - You are able to read, understand, and sign a consent form before the study begins - You are at least 12 years old and weigh at least 45 kg (about 99 lbs) - You have been regularly taking high-dose asthma preventer inhalers (steroid-based) for the past 12 months, with or with...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02808819 · AstraZeneca Phase 3 · 15 countries Completed
Completed Phase 3 Est. completion 18 June 2020
🇦🇷 AR🇦🇺 AU🇧🇬 BG🇨🇦 CA🇨🇱 CL🇨🇿 CZ🇫🇷 FR🇩🇪 DE +7 more

**Who might be able to join this trial:** - You must be willing and able to give your consent to take part before any study-related procedures begin. - You must have taken part in a previous related study (D3250C00021) for at least 16 weeks but no more than 40 weeks. - If you are a woman who could become pregnant, you...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05757102 · GlaxoSmithKline Phase 3 · 9 countries Recruiting
Recruiting Phase 3 Est. completion 22 January 2027
🇦🇷 AR🇦🇺 AU🇨🇱 CL🇮🇱 IL🇲🇽 MX🇳🇿 NZ🇰🇷 KR Turkey (Türkiye) +1 more

**Who might be able to join this trial:** - People who are between 12 and 17 years old (inclusive) at the time of signing the consent forms. - People who were diagnosed with asthma at least 1 year before the first study visit. - People who have been using a daily combination inhaler (containing both a steroid and a lo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07055542 · University of Melbourne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇦🇺 AU

**Who might be able to join this trial:** - Adults aged 18 to 70 years who have seasonal allergic rhinitis (hay fever) and agree to take part - People who are willing to have their lung function tested (breathing tests) - People who are willing to have a blood sample taken to help identify risk factors - People who are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT07245368 · Prana Therapies Inc Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇦🇺 AU🇳🇿 NZ

**Phase 1** Who might be able to join this trial: - People aged between 18 and 65 years old - People who are generally healthy with no significant medical history - People who are able and willing to attend all scheduled study visits and follow the study requirements - People who are willing to sign a written consent...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07309614 · Université de Sherbrooke Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 1 January 2029
🇦🇺 AU🇨🇦 CA🇬🇧 GB

**Who might be able to join this trial:** - You are between 18 and 79 years old (at the time of signing the consent form) - A doctor has diagnosed you with asthma (for at least 6 months), and there is medical record evidence showing your airways respond in a measurable way — for example, your breathing improves after...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01902290 · Amgen Phase 2 · 15 countries Terminated
Terminated Phase 2 Est. completion 15 May 2015
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇬🇷 GR Hong Kong🇮🇪 IE🇮🇹 IT +7 more

**Who might be able to join this trial:** - You have been diagnosed with asthma, and breathing tests at your screening visit show your lungs respond well to a bronchodilator (a medicine that opens the airways), with at least a 20% improvement. - Your lung function test results at screening fall within a specific range...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00595491 · Benjamin Medoff Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2028
🇺🇸 US

Who might be able to join this trial: **Group A – People with Allergic Asthma:** - Lung function (a breathing test called FEV1) must measure at least 75% of the expected normal value at the first study visit. - A clinical history of allergy symptoms related to cats or dust mites, confirmed by a positive skin prick all...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02241265 · University of Oklahoma Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇺🇸 US

"Who might be able to join this trial: - People who are over 18 years of age - People who have been diagnosed with severe asthma - People whose lung function test (called FEV1) shows reduced breathing capacity Who may not be able to join: - People who are under 18 years of age Important: Always verify eligibility wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02327897 · National Institute of Environmental Health Sciences (NIEHS) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2030
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 60 years old (male or female) - You have moderate-to-severe allergic asthma, with symptoms such as wheezing, chest tightness, shortness of breath, cough, or nighttime symptoms in the past year - You have had a breathing test (called a methacholine chal...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02351141 · Dr. Grace Parraga Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇨🇦 CA

**Who might be able to join this trial:** - You are a man or woman between 18 and 60 years old who has been diagnosed with asthma - You have smoked very little in your life — no more than 1 pack of cigarettes per year - You are willing to take part in the study and are able to sign a consent form to confirm this - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02419274 · LungenClinic Grosshansdorf Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇩🇪 DE

Who might be able to join this trial: - People who have a confirmed asthma diagnosis based on the current GINA Guidelines (2014) - People who are able to read and understand German - People who are able to understand and agree to the study's consent forms Who may not be able to join: - People who have had a respirator...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02496468 · LMU Klinikum Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇩🇪 DE

Who might be able to join this trial: - Parents must give consent for their child to participate, and children older than 8 years must also give their own consent - Children between 6 months and 18 years of age are eligible - The child must have been born at full term (at or after 37 weeks of pregnancy) - The child and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02947945 · National Jewish Health Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2018
🇺🇸 US

**Who might be able to join this trial:** - You must be able to read, understand, and sign a consent form agreeing to take part in the study. - You must be male or female and over 18 years old. - You must have been diagnosed with a condition called EGPA (a type of blood vessel inflammation linked to asthma) for at lea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03215836 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 March 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 65 years old, of any gender - People with a limited smoking history (less than 10 pack-years) who have not smoked in the past year - People already on blood pressure medication or managing diabetes through diet and exercise alone may still be considered...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03303586 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇨🇦 CA

"Who might be able to join this trial: - People who have never smoked, or who smoked very little in the past (fewer than 10 pack-years, which means roughly less than half a pack a day for 10 years) Who may not be able to join: - People whose high blood pressure is not well controlled by medication or other treatment...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03505216 · University of Bern Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇦🇹 AT🇨🇭 CH

Who might be able to join this trial: - The patient must be a child or teenager between 0 and 16 years old - The patient must live in Switzerland - The patient must be attending a children's lung specialist clinic because of breathing problems - Parents must be able to sign a consent form, and patients aged 14 or older...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03615742 · University of British Columbia Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2025
🇨🇦 CA

**Who might be able to join this trial:** - You are between 19 and 49 years old - You have been diagnosed with asthma by a doctor, and this will be confirmed during a screening visit through a physical exam, a breathing test (spirometry), a specific airway sensitivity test (methacholine challenge), and questionnaires...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT03885245 · University of Colorado, Denver Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2025
🇺🇸 US

**Who might be able to join this trial:** - You have agreed to participate and completed the consent process - Both men and women can join - You have been diagnosed with asthma by a doctor - You are able to do a breathing test (called spirometry) in a consistent, reliable way - Your breathing test results show your lun...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03983603 · Maastricht University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇳🇱 NL

**Who might be able to join this trial:** - People who have been diagnosed with allergic asthma (at a mild to moderate level, known as GINA step 1–4) that has been stable — meaning no changes in asthma control or lung function — for at least the past three months - People who have been taking prescribed asthma medicat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04045587 · University of British Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇦 CA

Who might be able to join this trial: - People who are 18 years of age or older - People who have severe or hard-to-control asthma, either at the highest level of standard asthma treatment (known as GINA Step 5), or at the second-highest level (GINA Step 4) where asthma is still not well controlled — meaning they still...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04307667 · University of Wisconsin, Madison Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are generally healthy with no existing health concerns that could affect study results. - People between 18 and 75 years old. - People who have been diagnosed with asthma by a doctor for at least six months before the screening visit, where the asthma is mild and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04331353 · Tulane University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2028
🇺🇸 US

**Who might be able to join this trial:** - Children between 5 and 17 years old who have asthma that is not well controlled - Children who have had at least one overnight hospital stay for asthma in the past six months, OR at least two unplanned clinic or emergency department visits for asthma in the past 12 months - C...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04380038 · University of Virginia Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 40 years old - People who have been diagnosed with asthma by a doctor for at least 6 months - People whose asthma has been well controlled (scoring 20 or above on the Asthma Control Test) for the 6 months before joining the trial - People whose lung fun...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04395937 · University of Liege Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇧🇪 BE

Who might be able to join this trial: - People who have been diagnosed with asthma - People between 18 and 65 years of age - People whose asthma symptoms are not well controlled, as measured by a standard questionnaire score (ACQ) above 1.5 - People who are already on a stable asthma treatment that includes at least on...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04435990 · Inmunotek S.L. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇪🇸 ES

**Who might be able to join this trial:** - People aged between 12 and 65 years, of any gender, who have given written consent to participate. - People with a confirmed history of allergic rhinitis (hay fever-type nasal symptoms, either occasional or ongoing, at a moderate-to-severe level) and/or eye symptoms caused b...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04442646 · Istituti Clinici Scientifici Maugeri SpA Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2026
🇮🇹 IT

"Who might be able to join this trial: - People who have been diagnosed with asthma according to standard medical guidelines (GINA or ATS guidelines) - People who are 18 years of age or older Who may not be able to join: - People who have a cognitive impairment (a condition that affects thinking, memory, or understand...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04565483 · Nantes University Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 October 2026
🇫🇷 FR

**Who might be able to join this trial:** - People aged between 18 and 75 years old. - People who have been diagnosed with severe asthma, meaning their asthma requires high doses of inhaled corticosteroid medication (above 1000 micrograms per day of Beclomethasone or an equivalent) combined with other long-acting medi...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04578171 · Laval University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇨🇦 CA

"Who might be able to join this trial: - People who have been formally diagnosed with severe asthma, as defined by the Canadian Thoracic Society guidelines. - People whose treating doctor has determined them to be eligible for treatment with mepolizumab. - People who are able to understand and willing to sign the conse...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04639791 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
Hong Kong

Who might be able to join this trial: - You must be 18 years of age or older and have been diagnosed with asthma, confirmed by medical records showing that your airways have variable obstruction - Your asthma must be at a more severe level, meaning you are already on a high level of asthma treatment (steps 4 or 5 of st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04706988 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
Hong Kong

**Who might be able to join this trial:** - People aged between 18 and 80 years old who have been diagnosed with asthma according to the 2020 Global Initiative for Asthma (GINA) guidelines. - People whose asthma has been confirmed by medical testing showing that their airways respond to a reliever medication (with brea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04763447 · Assistance Publique - Hôpitaux de Paris Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 20 May 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who are over 18 years old - People who have been prescribed omalizumab (OMA) by a lung specialist (pulmonologist) for severe allergic asthma for at least 33 months - People whose asthma is well controlled on their current treatment, shown by a score of 18 or higher on...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04784364 · Icahn School of Medicine at Mount Sinai Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2030
🇺🇸 US

Who might be able to join this trial: - People aged 12 years or older. - People who are able to give their informed consent to participate in the study (for younger participants, a parent or guardian may need to consent on their behalf — confirm with trial site). - People who receive their medical care at Mount Sinai....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04796844 · Societa Italiana di Pneumologia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2021
🇮🇹 IT

"Who might be able to join this trial: - You must be an adult (18 years of age or older) - You must have been diagnosed with asthma, confirmed using standard medical guidelines (the GINA 2020 diagnostic process) - You must have already taken part in, or currently be taking part in, another observational research study...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04891237 · Inmunotek S.L. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2026
🇪🇸 ES

**Who might be able to join this trial:** - People who have signed the informed consent form for the trial. - People aged between 12 and 65 years (any sex). - People with a confirmed history of nasal or eye allergy symptoms (such as hay fever or allergic eye inflammation, ranging from moderate to severe) caused by gra...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04898283 · Inmunotek S.L. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2026
🇪🇸 ES

**Who might be able to join this trial:** - People aged between 12 and 65 years, of any gender, who give written agreement to take part. - People with a history of moderate to severe hay fever (nose and/or eye symptoms) that comes and goes or is ongoing, caused by grass pollen and cypress-type tree pollen — with or wi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04912596 · Intech Biopharm Ltd. Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 January 2025
🇮🇳 IN🇹🇼 TW

Who might be able to join this trial: - You are a man, or a woman who is not pregnant or breastfeeding, between 20 and 65 years old. - You have been officially diagnosed with mild asthma, according to recognised asthma guidelines. - Your asthma has been stable for at least 1 month, and you are using a low-dose inhaled...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05004714 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇺🇸 US

Who might be able to join this trial: - You are 18 years old or older - You are either a staff member at a Head Start program, or you are a caregiver of a child who is currently enrolled in Head Start and has asthma - You are able to understand and agree to participate in the study on your own - You are comfortable wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05008965 · Oneness Biotech Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇹🇼 TW

**Who might be able to join this trial:** - People aged 18 to 75 years old. - People who have been diagnosed with moderate-to-severe allergic asthma for at least 12 months before the first study visit. - People whose medical records show that their airways respond to a reliever inhaler (such as albuterol/salbutamol),...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05028153 · Copenhagen Studies on Asthma in Childhood Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 13 November 2026
🇩🇰 DK

**Who might be able to join this trial:** - Children who have had one or more episodes of asthma-like symptoms, or who have been treated with certain asthma-related medications (a fast-acting reliever inhaler alone, or combined with a preventer inhaler, and possibly an additional medication called a leukotriene recepto...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05043116 · Copenhagen Studies on Asthma in Childhood Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 16 October 2028
🇩🇰 DK

**Who might be able to join this trial:** - Children between 1 and 5 years old who have been admitted to a children's hospital ward because of a sudden episode of asthma-like symptoms (such as bothersome coughing, wheezing, and/or difficulty breathing that affects the child's wellbeing) - Children who are currently rec...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05114096 · McMaster University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2026
🇨🇦 CA

**Who might be able to join this trial:** - You are pregnant, between 18 and 55 years old, and are carrying one baby or twins - Your pregnancy is between 22 weeks and 0 days and 34 weeks and 6 days along, and you are considered at risk of giving birth early - You have received only one dose of a medication called Celes...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05140889 · Fondazione IRCCS Policlinico San Matteo di Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇮🇹 IT

Who might be able to join this trial: - The participant must be between 6 and 17 years old - The participant must have been formally diagnosed with severe asthma, following specific international medical guidelines (ERS/ATS) Who may not be able to join: - Children who have other conditions that can look or behave like...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05192499 · University Hospital, Brest Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 February 2028
🇫🇷 FR

Who might be able to join this trial: - Children who are older than 1 year and younger than 3 years of age - Children who have been diagnosed with asthma by a paediatrician - Children whose parent or guardian has given their consent to participate - Children who are enrolled in the French social security system Who ma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05217810 · Novartis Pharmaceuticals Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 December 2026
🇰🇷 KR

**Who might be able to join this trial:** - You are 12 years old or older and have been diagnosed with asthma by a doctor - Your doctor has prescribed you a specific inhaled asthma medication called Atectura (indacaterol/mometasone), used with a Breezhaler device, at one of the approved doses - You are willing to sign...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05222529 · Novartis Pharmaceuticals Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 30 July 2027
🇧🇬 BG🇨🇴 CO Guatemala🇭🇺 HU🇵🇱 PL🇿🇦 ZA🇪🇸 ES🇬🇧 GB

Who might be able to join this trial: - People who have had a confirmed asthma diagnosis for at least 6 months. - A parent or legal guardian must sign a consent form on behalf of the child, and the child may also need to give their agreement to take part, depending on local rules. - The child must be taking a stable, l...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05259904 · University of Colorado, Denver Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have completed the consent process and signed the required paperwork - Men and women between 18 and 70 years old (inclusive) - People who developed ongoing breathing symptoms — such as cough, shortness of breath, wheezing, and/or chest tightness — during or after...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05272241 · National Institute of Allergy and Infectious Diseases (NIAID) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who are willing and able to give their own consent to participate at the time of enrollment - People under 18 years old, as long as a legal guardian is present and willing to give consent on their behalf at the time of enrollment - People whose main ho...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05274425 · Novartis Pharmaceuticals Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 March 2027
🇰🇷 KR

**Who might be able to join this trial:** - Adults aged 18 or older who have been diagnosed with asthma by a doctor, and whose doctor has prescribed them Enerzair inhalation capsules (a combination inhaler containing indacaterol acetate, glycopyrronium bromide, and mometasone furoate) used with a Breezhaler device, in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05341726 · Columbia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** *For patients:* - You are 18 years old or older - You identify your race as Black (this includes African American, African, Caribbean, West Indian, or mixed race with Black as one part), and you identify your ethnicity as Hispanic or non-Hispanic - A doctor has diagnosed you w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05364632 · University of Sao Paulo General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇧🇷 BR

**Who might be able to join this trial:** - People who are not currently doing regular physical activity - People whose asthma is not well controlled (based on a standard asthma symptom score above 1.5) - People who have been formally diagnosed with asthma according to recognised international guidelines (GINA 2020) -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05445583 · University of Michigan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who identify as African American - People between 18 and 30 years old - People with asthma that is not well controlled, meaning a score of less than 19 on a standard asthma control questionnaire called the ACT - People who own or have reliable access to a cell phone for th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05496582 · Shanghai University of Traditional Chinese Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇨🇳 CN

Who might be able to join this trial: - People between the ages of 14 and 75 years old, either male or female - People who have been formally diagnosed with bronchial asthma - People whose asthma diagnosis meets the Global Initiative for Asthma (GINA) guidelines, including a breathing test showing the airways respond t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05525169 · Nantes University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 November 2026
🇫🇷 FR

Who might be able to join this trial: - People who are over 18 years of age - People who have been diagnosed with asthma for at least 12 months, as confirmed by a doctor - People who have had at least 4 asthma flare-ups in the past year - People who sleep in the same home at least 6 nights per week Who may not be able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05562466 · Novartis Pharmaceuticals Phase 3 · 17 countries Recruiting
Recruiting Phase 3 Est. completion 1 February 2028
🇦🇷 AR🇦🇹 AT🇧🇷 BR🇧🇬 BG🇨🇴 CO🇨🇿 CZ🇬🇷 GR Guatemala +9 more

**Who might be able to join this trial:** - Children aged 6 years old up to (but not including) 12 years old at the time of joining the trial - Children who have had a confirmed asthma diagnosis for at least 12 months before enrolling in the study - Children whose parent or legal guardian is willing and able to attend...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05572177 · University of South Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇺🇸 US

Who might be able to join this trial: - People who are at least 12 years old but under 18 years old at the time of enrolment - People who have been diagnosed with mild, moderate, or severe persistent asthma, confirmed by a clinic doctor - People who speak English - People who are not planning to move out of the Tampa B...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05608668 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - Children between 8 and 17 years old who have obesity (a body weight that falls at or above the 95th percentile for their age and sex) and mild asthma. - The child's parent or legal guardian must give written permission for them to take part, and the child must also agree to p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05632081 · Ain Shams University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇸🇦 SA

**Who might be able to join this trial:** - People who are able to give written consent to participate - People aged 13 or older - People who are able to correctly use the study inhalers, complete an electronic diary, and attend all required visits - People with a confirmed diagnosis of mild or moderate asthma, managed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05667701 · Rajesh Kumar Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2028
🇺🇸 US

**Who might be able to join this trial:** - The parent or guardian must be an adult (18 or older) who can understand and agree to the study requirements in writing. - The baby must have been born at full term (at or after 37 weeks of pregnancy) and be younger than 12 months old when joining the study. - The baby must...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05691218 · Poitiers University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 February 2026
🇫🇷 FR

Who might be able to join this trial: - People aged 18 or older. - People admitted to an Emergency Department where doctors suspect they are having an acute asthma attack, based on recognised international asthma guidelines (GINA criteria). - People who, after an initial breathing treatment (nebulised terbutaline, give...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05734261 · University Hospital, Montpellier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 February 2026
🇫🇷 FR

**Who might be able to join this trial:** - Children aged between 6 and 16 years - Children whose lung function test (FEV1) result is above 60% of the expected value - Children who have been referred to a lung function laboratory for a specific breathing test that checks for airway sensitivity, using a substance called...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05761028 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 May 2032
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a consent form agreeing to take part - People aged between 12 and 75 years old (male or female) who weigh at least 40 kg - People who have been diagnosed with asthma for at least 1 year, where the diagnosis...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05768399 · Children's Hospital of Chongqing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - Children aged 4 to 12 years old who have been newly diagnosed with bronchial asthma or are experiencing a recurring episode of it - Children whose diagnosis meets the official guidelines set out in the 2016 Guidelines for the Diagnosis and Prevention of Bronchial Asthma in Childr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05814510 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: **For adults:** - You are 18 years old or older - You are currently caring for a child who has asthma, OR you work as a staff member at a Baltimore City K-8 public school that is part of the Asthma CHAMPS program **For children:** - The child has been diagnosed with asthma - The...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05844891 · University of Rochester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2028
🇺🇸 US

**Who might be able to join this trial:** - The child has been diagnosed with asthma by a doctor, confirmed through medical records and/or a parent or caregiver's report. - The child is currently at the emergency department for a sudden worsening of asthma that requires treatment with quick-relief (rescue) medication....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05851443 · Incyte Corporation Phase 2 · 7 countries Recruiting
Recruiting Phase 2 Est. completion 15 June 2026
🇦🇷 AR🇨🇦 CA🇩🇪 DE🇯🇵 JP🇵🇱 PL🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with asthma by a doctor and have been treated with a medium- to high-dose combination inhaler (containing both a steroid and a long-acting reliever) for at least 12 months before the screening visit. - People whose lung function test (measuring...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05937334 · Beijing Chao Yang Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are over 18 years old - You have been diagnosed with asthma according to the 2023 GINA diagnostic guidelines (confirm with trial site) - You are willing to sign a consent form, follow the study plan, and attend follow-up appointments for 2 years **Who may not be able to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05945355 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2027
🇺🇸 US

**Who might be able to join this trial:** - Children and teenagers between 6 and 17 years old - People who have been diagnosed with asthma by a doctor - People whose asthma currently requires 2 or more regular (controller) medications to manage, which typically indicates moderate to severe persistent asthma - People wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05991115 · Kavita Parikh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇺🇸 US

Who might be able to join this trial: - You speak English or Spanish - You are at least 18 years old - You live in Washington D.C., Maryland, or Virginia - You have a child between the ages of 4 and 12 who is currently in the hospital because of an asthma attack Who may not be able to join: - Your child (ages 4–12) ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05999032 · Rhode Island Hospital Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
Puerto Rico🇺🇸 US

Who might be able to join this trial: - Children who are between 2 and 12 years old - Children who live in one of the specific geographic areas identified by the trial - Children whose asthma is considered not well controlled or poorly controlled, based on screening criteria Who may not be able to join: - Children who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06003569 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - You have a child with asthma that is not well controlled, or whose asthma intake form at school shows signs of significant impact on daily life - Your child is between 5 and 12 years old - Your child attends one of the participating schools in rural Colorado, which were chosen ba...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06015256 · Institut National de la Santé Et de la Recherche Médicale, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇫🇷 FR

**Who might be able to join this trial:** - You have read, understood, and signed a consent form before any study procedures begin - You are covered by or eligible for a social security/health insurance scheme - You are 18 years of age or older - *(For people with asthma)* You have been diagnosed with severe asthma, c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06023589 · AstraZeneca Phase 3 · 22 countries Recruiting
Recruiting Phase 3 Est. completion 31 May 2028
🇦🇷 AR🇧🇷 BR🇨🇦 CA🇨🇳 CN🇨🇴 CO🇫🇷 FR🇭🇺 HU🇮🇹 IT +14 more

**Who might be able to join this trial:** - A parent or caregiver must give written permission for the child to take part, and the child must also agree to join if they are old enough to do so. - The child must be between 5 and just under 12 years old at the time consent is signed and at the start of the trial. - The...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06035289 · German Asthma Net e.V. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇩🇪 DE

**Who might be able to join this trial:** **Children and teenagers (ages 6–18):** - Children and teenagers between 6 and 18 years old at the time of joining the trial - Asthma has been formally diagnosed by a doctor - Other conditions that could explain the symptoms have been ruled out - The child has been taking thei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06037967 · University Hospital, Toulouse Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2038
🇫🇷 FR

Who might be able to join this trial: - People who have had a positive skin prick test or a blood test showing an allergic response, regardless of what they are allergic to - People who are being investigated for a possible allergic condition, where a doctor has recommended a skin prick test, allergy blood test, or a s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06068335 · University of Central Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People with no history of allergic disease (referred to as healthy controls), or people who have been clinically diagnosed with allergies, or people who have been clinically diagnosed with asthma Who may not be able to join: - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06105710 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** **For healthy volunteers:** - Adults aged 18 to 70 years (male or female) - People who are able to give written consent and follow the study requirements - People whose airways do not show unusual sensitivity to a breathing test substance called methacholine (at a level above...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06106646 · Oregon Health and Science University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

Who might be able to join this trial: - Women who took part in the original VCSIP study during pregnancy, either receiving vitamin C or a placebo (dummy pill), and their children born from that study - Pregnant non-smokers and their children who were enrolled as a comparison group in the original VCSIP study Who may n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06116292 · Hospital Universitari de Bellvitge Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇪🇸 ES

**Who might be able to join this trial:** - You are 18 years old or older and have been diagnosed with asthma according to specific medical guidelines (GEMA 5.2 2022) (confirm with trial site) - You are a patient being seen in the lung/breathing department (pulmonology service) at the trial centre - You have never rece...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06126692 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇩🇰 DK🇳🇱 NL

**Who might be able to join this trial:** *People with severe asthma:* - You have severe asthma that requires high-dose inhaled steroids (at least 1600 micrograms of Budesonide per day) plus at least one other asthma controller medication. - You have had at least 2 asthma attacks in the past year, or you take steroid...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06136091 · National Institute of Allergy and Infectious Diseases (NIAID) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - The participant (and/or their parent or guardian, if applicable) must be able to understand and agree to take part in the study. - People who live in one of the specific neighbourhoods (census tracts) pre-selected for this study, as outlined in the study's operating guidelin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06137040 · University of Oklahoma Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 May 2025
🇺🇸 US

Who might be able to join this trial: - The child is between 5 and 17 years old - The child has come to the Emergency Department with a breathing problem that has been rated as "moderate" severity - The child's parent(s) or caregiver(s) speak English Who may not be able to join: - The child has a long-term medical con...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06151405 · Pennington Biomedical Research Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - Adults between 18 and 65 years old - People with a body mass index (a height-to-weight measurement) between 18.5 and 29.99 - People who have been diagnosed with asthma by a specialist, with this recorded in their medical history - People whose asthma is partly controlled or uncon...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06152653 · University of California, San Francisco Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** **Asthma Group:** - Adults aged 18 to 85 with a confirmed history of asthma (based on self-report or medical records) - People who are able to give written consent and follow the study requirements - People who are able to complete a specific type of breathing test (spirometry...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06191315 · Sanofi Phase 3 · 16 countries Recruiting
Recruiting Phase 3 Est. completion 21 December 2028
🇦🇷 AR🇧🇷 BR🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇬🇷 GR🇭🇺 HU +8 more

Who might be able to join this trial: - The child must be between 2 and under 6 years of age. - The child must have a diagnosis of asthma or recurring severe wheezing episodes that have not been well controlled by inhaled corticosteroid (preventer) medication used regularly for at least 3 months, with the same dose sta...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06196034 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 January 2028
Hong Kong

**Who might be able to join this trial:** - People who have a confirmed diagnosis of asthma, meaning they have a consistent history of the condition and past test results showing that their airways vary in how open or blocked they are, confirmed by breathing tests when their asthma is stable. - People who are able to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06216535 · University of Texas Southwestern Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have moderate to severe persistent asthma - People who are currently being treated with medium to high doses of inhaled corticosteroids (preventer inhalers) combined with a long-acting bronchodilator (LABA) - People who have had three or more serious asthma attack...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06230458 · Franciscus Gasthuis & Vlietland (Hospital) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇳🇱 NL

Who might be able to join this trial: - You are 18 years old or older - You are visiting a lung specialist's clinic because doctors suspect you may have asthma (but you have not been diagnosed yet) - You are eligible to take part whether or not you smoke, and regardless of your body weight Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06237660 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇬🇧 GB

Who might be able to join this trial: - The child must be between 1 and 5 years old - The child has been admitted to hospital more than twice in the last year due to sudden episodes of wheezing, OR - The child has had at least one hospital stay in the last year that required intensive monitoring or treatment through a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06239844 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇺🇸 US

Who might be able to join this trial: - The child in the family must be between 4 and 12 years old. - The child must have persistent asthma, meaning a doctor has currently prescribed them a daily asthma control medication. - The parent or legal guardian must be at least 18 years old. - The parent or legal guardian must...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06271213 · NHS Greater Glasgow and Clyde Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇬🇧 GB

**Who might be able to join this trial:** - Infants, children, or young people (from birth up to 16 years old) admitted to the Royal Hospital for Children (RHC), Glasgow for a planned bronchoscopy or gastrointestinal (gut) camera procedure - Infants or children attending for a planned or emergency bone/joint operation...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06278662 · Mattienne van der Kamp Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2034
🇳🇱 NL

Who might be able to join this trial: - The child is between 4 and 18 years old - The child is currently a patient in the children's department at Medisch Spectrum Twente hospital - The child has been diagnosed with asthma by a children's doctor, based on typical symptoms such as wheezing (especially at night), shortne...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06286085 · Portsmouth Hospitals NHS Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 May 2027
🇬🇧 GB

Who might be able to join this trial: - People aged 18 years or older. - People who have attended a full asthma assessment at the Portsmouth asthma service from November 2021 onwards. - People who are willing to allow their data to be used in this study (through an opt-out form or electronic consent). - People who were...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06299592 · University of Wisconsin, Madison Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old - You are able to understand the study and are willing to sign a consent form agreeing to take part - You are able to cooperate with the study procedures and requirements - You have a specific genetic profile related to how a certain protei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06307665 · AstraZeneca Phase 3 · 4 countries Recruiting
Recruiting Phase 3 Est. completion 13 October 2027
🇨🇳 CN🇲🇽 MX🇿🇦 ZA🇺🇸 US

**Who might be able to join this trial:** - People who have had a confirmed asthma diagnosis for at least 12 months. - People who have been on a stable asthma maintenance treatment (using an inhaled corticosteroid, with or without other add-on asthma medicines) for at least 3 months, with the dose unchanged for at lea...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06311162 · Insel Gruppe AG, University Hospital Bern Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2028
🇨🇭 CH

Who might be able to join this trial: - The child must be younger than 6 years old - The child must be regularly exposed to second-hand smoke at home, meaning at least one parent smokes - At least one parent must be able to speak German - Children of any sex or ethnic background are welcome - A parent or guardian must...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06314477 · Hospital Clinic of Barcelona Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇪🇸 ES

Who might be able to join this trial: - People who are older than 18 years of age - People who have been diagnosed with severe, uncontrolled asthma according to recognised asthma guidelines, and who have not been hospitalised in the month before joining the study - People whose sleep monitoring shows 15 or more episode...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06317909 · Fraunhofer-Institute of Toxicology and Experimental Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇩🇪 DE

**Who might be able to join this trial:** - People who are willing and able to give written consent to participate - Adults between 18 and 65 years of age - Women who are not pregnant (confirmed by a pregnancy test), not breastfeeding, and either unable to become pregnant naturally or using a highly effective form of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06323213 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2027
🇨🇳 CN

Who might be able to join this trial: - People who are able to give written agreement to take part before the study begins. - Adults aged 18 to 75 years old at the time of signing the consent form. - People who have had a confirmed diagnosis of asthma for at least one year before the screening visit. - People who have...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06334705 · Institut National de la Santé Et de la Recherche Médicale, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 February 2027
🇫🇷 FR

Who might be able to join this trial: - People who took part in at least one of the previous EGEA surveys - People who are enrolled in, or covered as a dependent under, a social security scheme Who may not be able to join: - People who are currently detained or have had their freedom restricted by a court or governmen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06372249 · Phoenix Children's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 May 2027
🇺🇸 US

Who might be able to join this trial: - Children and teenagers between the ages of 6 and 17 - People who have been diagnosed with asthma within the last 2 years - People who have either a breath test result showing airway inflammation above a certain level (FeNO greater than 50 ppb), or a confirmed history of environme...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06377345 · SingHealth Polyclinics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2025
🇸🇬 SG

Who might be able to join this trial: - People who have been diagnosed with asthma - Children aged 7 to 17, or adults aged 18 and older - People who are having an asthma flare-up on the day of their visit to the trial site - People who are willing to use a device called AeviceMD - People who have a smartphone that can...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06385236 · University of California, San Diego Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are willing to follow all study procedures and are available for the full duration of the trial. - People whose asthma medications have not changed in the past 2 months, and who are currently using a medium or high dose inhaled corticosteroid (a preventer inhaler)...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06388460 · University of Massachusetts, Worcester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇺🇸 US

**Who might be able to join this trial:** **For the child:** - Children between 5 and 14 years old who are in grades K–8 - Children who have been prescribed a daily inhaled steroid (a type of controller medication) for asthma - Children whose asthma has not been well controlled recently — this is measured by a standar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06419413 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old - Your lung function test results (a breathing test called FEV1) meet acceptable levels as defined by international standards - You are willing and able to follow the study procedures - A doctor has diagnosed you with asthma at least 3 mont...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06422078 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇩🇪 DE

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People with a confirmed diagnosis of severe eosinophilic asthma (a type of asthma involving high levels of certain immune cells), as defined by major respiratory medical guidelines, who are already being treated with high-dose inhaled...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06425562 · Universitair Ziekenhuis Brussel Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇧🇪 BE

Who might be able to join this trial: - Adults who have been diagnosed with asthma, have a scheduled outpatient hospital appointment, and whose doctor has decided to change their asthma medication (either increasing or decreasing the strength or dose of their treatment) Who may not be able to join: - People whose asth...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06427018 · Lei-Miao Yin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - The trial uses lung tissue samples (not collected specifically for this study, but obtained during surgery done for other medical reasons). - Samples must come from patients who were between 18 and 70 years old at the time of the tissue collection, regardless of gender. - Lung ti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06429475 · University of KwaZulu Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2028
🇿🇦 ZA

**Who might be able to join this trial:** - You are between 6 and 18 years old at the time of signing up for the study - You have already been diagnosed with asthma and are currently on treatment for it - You have recently been diagnosed with asthma for the first time - Your asthma diagnosis has been confirmed through...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06433921 · GlaxoSmithKline Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 26 February 2027
🇬🇧 GB

**Who might be able to join this trial:** - You are male or female, aged 18 to 65 years old at the time of screening. - You weigh at least 50 kg (about 110 lbs) at the time of screening. - Your Body Mass Index (BMI) — a measure of body weight relative to height — is between 19.0 and 35.0 at the time of screening. - Yo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06437444 · Basque Health Service Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 May 2026
🇪🇸 ES

Who might be able to join this trial: - Children between 2 and 14 years old who were seen for asthma care between 7 May 2023 and 7 May 2025. - Children who had a wheezing episode and had previously been diagnosed with asthma, or had experienced a previous wheezing episode. - Children aged over 2 years who had their fir...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06441812 · Guangdong Hengrui Pharmaceutical Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older, male or female. - You weigh at least 40 kg (approximately 88 lbs). - You have been diagnosed with asthma (according to specific medical guidelines) and have had asthma for at least 1 year. - You have been taking a medium or high dose inhaled...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06447974 · Queen Mary University of London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇬🇧 GB

Who might be able to join this trial: - A parent or guardian must be able to give written permission for their child to take part - The child must have been referred by a paediatric asthma team - The child must be between 4 and 17 years old at the time of joining the study - The child must have been diagnosed with a lo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06449573 · Hacettepe University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2025
Turkey (Türkiye)

Who might be able to join this trial: - People who do not have any respiratory, cardiovascular, or metabolic diseases - People who are regular non-smokers Who may not be able to join: - People who do not give their consent to participate in the trial - People who are pregnant Important: Always verify eligibility with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06456450 · Taichung Veterans General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2043
🇹🇼 TW

**Who might be able to join this trial:** - People who have given their written agreement to take part before any study-related procedures begin. - People whose asthma has been officially confirmed as a severe case by the National Health Insurance Administration or by a member of the study review board. - People who a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06471257 · AstraZeneca Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 30 October 2026
🇨🇳 CN Hong Kong

Who might be able to join this trial: - People who have been diagnosed with asthma by a doctor for at least 12 months before the first study visit - People who have been taking one of the specified asthma maintenance (regular, ongoing) treatments for at least 3 months, with the same dose for at least the last 4 weeks b...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06472310 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇷🇺 RU

Who might be able to join this trial: - People who are 18 years of age or older at the time of joining the trial - People who have provided signed and dated written consent to participate, in line with the required guidelines - People who have been diagnosed with severe, uncontrolled asthma for at least 52 weeks before...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06516848 · Istanbul Medipol University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
Turkey (Türkiye)

**Who might be able to join this trial:** - People aged between 18 and 65 years - People who have been diagnosed with severe, persistent, non-allergic asthma by a lung specialist, following recognised international asthma guidelines - People whose asthma test results show certain inflammation markers — specifically, l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06521229 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇷🇺 RU

Who might be able to join this trial: - People who are 18 years of age or older at the time of joining the trial - People who have given written consent to participate, signed and dated, before the trial begins - People who have been diagnosed with mild or moderate asthma that is not well controlled, based on a standar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06535087 · Wenjing Zhou Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 June 2025
🇨🇳 CN

**Who might be able to join this trial:** *Children:* - Children aged 5 to 16 years - Children who have been diagnosed with asthma, allergic rhinitis (hay fever), or both by a lung or allergy specialist, with symptoms lasting at least 4 weeks - Children whose parent or guardian has signed the consent form agreeing to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06539312 · State University of New York at Buffalo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2028
🇺🇸 US

"Who might be able to join this trial: - People with asthma that is not well controlled (meaning symptoms are not being managed effectively by current treatment) Who may not be able to join: - People who have another long-term lung condition, such as cystic fibrosis Important: Always verify eligibility with the trial...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06552013 · University of Washington Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇺🇸 US

Who might be able to join this trial: - Children between 6 and 17 years old - Children who have been diagnosed with asthma by a doctor and whose asthma is not well controlled, meaning they have had asthma symptoms on more than four days in the past two weeks, have needed to use asthma relief medication on more than fou...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06563544 · Erasmus Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇳🇱 NL

**Who might be able to join this trial:** - You are 18 years of age or older - You have agreed to take part and signed a consent form - You are currently on a breathing machine (ventilator) through a tube placed in your throat - The reason you needed the breathing tube was due to a severe flare-up of asthma or COPD - Y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06573450 · Henan University of Traditional Chinese Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2025
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with allergic rhinitis (AR), bronchial asthma (BA), or combined allergic rhinitis and asthma syndrome (CARAS), based on standard Western medical diagnostic criteria - People whose condition also matches one of three specific Traditional Chinese Medicine patte...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06609941 · Foundation University Islamabad Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇵🇰 PK

Who might be able to join this trial: - Adults between 18 and 45 years old - Both men and women are welcome to apply - People who experience breathlessness ranging from mild to severe, as measured by a standard breathing difficulty scale called the Modified MRC Dyspnea Scale (Grades 1 to 4) - People diagnosed with mild...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06612294 · Icahn School of Medicine at Mount Sinai Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 December 2028
🇺🇸 US

**Who might be able to join this trial:** - You are older than 60 years of age - You speak English or Spanish - You have been told by a doctor that you have asthma, or you believe you have asthma, and this has been the case for more than 1 year - Your asthma is currently not well controlled **Who may not be able to jo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06623799 · QHSLab, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 January 2027
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who are currently receiving care from a primary care provider (such as a GP) - People who have agreed to allow their health data to be used in the research repository Who may not be able to join: - People who have not agreed to al...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06623981 · Children's National Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2026
🇺🇸 US

**Who might be able to join this trial:** *For the mother/primary caregiver:* - The primary caregiver of the child with asthma must be a woman (self-identified) who identifies as Black - The caregiver must be 18 years of age or older - The caregiver must speak English - The caregiver must be the main person looking af...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06624735 · Sohag University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 July 2025
🇪🇬 EG

**Who might be able to join this trial:** - Children who are between 4 and 12 years old - Children who have been officially diagnosed with asthma **Who may not be able to join:** - Children who are younger than 4 years old or older than 12 years old - Children who have been diagnosed with any other long-term medical c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06625216 · Società Italiana di Allergologia, Asma e Immunologia Clinica Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 February 2027
🇮🇹 IT

**Who might be able to join this trial:** - You have read, understood, and signed the consent and privacy forms for the study - You are older than 12 years of age - You have been diagnosed with severe asthma, meaning you are already taking strong asthma medications (high-dose inhaled steroids plus at least one other co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06653322 · Guangdong Hengrui Pharmaceutical Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are at least 12 years old - People who weigh at least 40 kg (approximately 88 pounds) - People who have had a confirmed asthma diagnosis for at least 1 year - People who have been taking a medium or high dose of inhaled corticosteroid (a common asthma preventer me...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06660537 · Foundation University Islamabad Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇵🇰 PK

Who might be able to join this trial: - Adults between the ages of 18 and 59 years old - Both men and women are eligible - People who experience breathlessness rated at Grade 1 through Grade 4 on a standard breathlessness scale (called the Modified MRC Dyspnea Scale) - People with mild asthma, classified as either mild...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06664619 · Teva Branded Pharmaceutical Products R&D LLC Phase 3 · 13 countries Recruiting
Recruiting Phase 3 Est. completion 19 September 2026
🇦🇷 AR🇧🇬 BG🇨🇿 CZ🇩🇪 DE🇮🇱 IL🇲🇽 MX🇵🇱 PL🇷🇴 RO +5 more

Who might be able to join this trial: - People who have been diagnosed with asthma for at least 6 months. - People who currently use a reliever (rescue) inhaler, such as salbutamol or a similar medication, with or without regular asthma preventer medication. - Female participants who are not currently pregnant, not bre...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06681545 · Manchester University NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2025
🇬🇧 GB

Who might be able to join this trial: - People who have been diagnosed with severe or uncontrolled asthma and are currently receiving care from the Manchester or Liverpool severe asthma services - People aged between 16 and 25 years old - People who have given their informed consent to take part in the study Who may n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06705764 · University of Alberta Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 November 2026
🇨🇦 CA

**Who might be able to join this trial:** - People who are willing and able to give their informed consent before any study procedures begin - People aged 18 to 55 years (male or female) - People who have been diagnosed with asthma by a doctor - People who have been prescribed a high-dose inhaled corticosteroid (a str...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06750289 · AstraZeneca Phase 3 · 13 countries Recruiting
Recruiting Phase 3 Est. completion 3 November 2028
🇧🇬 BG🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE Hong Kong🇮🇪 IE🇮🇹 IT +5 more

**Who might be able to join this trial:** - People who have given written agreement to take part in the study - People who are between 12 and 75 years of age - People who have a confirmed asthma diagnosis from a doctor, and have needed at least a medium-strength inhaled corticosteroid (ICS) combined with a long-acting...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06753214 · Can Tho University of Medicine and Pharmacy Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇻🇳 VN

Who might be able to join this trial: - Children diagnosed with asthma (following standard international guidelines) whose asthma is currently not well controlled, and who have been seen and followed up at the children's asthma clinic for at least 1 month. Who may not be able to join: - Children who are unable or unwi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06766136 · Nigde Omer Halisdemir University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2025
Turkey (Türkiye)

Who might be able to join this trial: - Adults between 18 and 64 years of age - People who have been diagnosed with asthma for at least 6 months - People who live in the city center - People whose asthma is considered partly or not well controlled, based on a standard asthma control questionnaire score of 20–24 (partia...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06778746 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 December 2026
Hong Kong

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with severe asthma according to internationally recognised guidelines (called the GINA guidelines) - People who have received at least one dose of a biologic therapy (a specialised type of medication) for their asthma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06783101 · Children's Hospital Los Angeles Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2025
🇺🇸 US

Who might be able to join this trial: - The participant must be a young person between the ages of 10 and 17 years old - The participant must have a diagnosis of mild-to-moderate intellectual disability and/or a developmental disability, which may include autism - The participant must have a diagnosis of moderate-to-se...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06785272 · Suzanne Schuh Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2027
🇨🇦 CA

Who might be able to join this trial: - Children aged between 2 and 17 years old (before their 18th birthday). - Children who have been diagnosed with asthma or an asthma-like condition by a doctor, including an emergency department doctor. - Children whose asthma is considered moderate to severe after already receivin...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06788093 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

Who might be able to join this trial: - People who are being seen in an emergency department or admitted to a hospital inpatient team. - People whose electronic health record shows signs that suggest a lower respiratory tract infection, meaning their reason for visiting includes symptoms such as cough or shortness of b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06796894 · Hacettepe University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2026
Turkey (Türkiye)

Who might be able to join this trial: - People between the ages of 35 and 75 years old - People who have been diagnosed with allergic or eosinophilic asthma, as defined by the Global Strategy for the Prevention and Treatment of Asthma (GINA) guidelines Who may not be able to join: - People with a known cognitive impai...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06816342 · Beni-Suef University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 10 February 2025
🇪🇬 EG

Who might be able to join this trial: - People aged between 6 and 80 years old who have been diagnosed with mild or moderate asthma Who may not be able to join: - People with severe asthma or those who have been admitted to an intensive care unit - People with ischemic heart disease (a condition where the heart does n...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06820593 · Ann & Robert H Lurie Children's Hospital of Chicago Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** **For parent-child pairs:** - The caregiver (parent or legal guardian) must be at least 18 years old - The child must have a diagnosis of asthma recorded in their clinic health records - The child must be between 4 and 17 years old at the time of joining the study - The child...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06829784 · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co.,... Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to sign a consent form showing they understand the trial's purpose, process, and possible side effects before it begins - People aged between 18 and 75 years old (any gender) - People who have had a formal asthma diagnosis from a doctor for at least 12...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06837922 · Shanghai Mabgeek Biotech.Co.Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 15 November 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 12 to 75 years old (male or female) who weigh at least 30 kg - People who have been diagnosed with asthma for at least one year, with a diagnosis that meets current international asthma guidelines (2024 GINA) - People who have been taking a medium-to-high dose of...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06840717 · Guangzhou Institute of Respiratory Disease Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Children who have been diagnosed with asthma based on the 2023 GINA guidelines (an internationally recognised set of standards for diagnosing asthma) - Children whose wheezing and coughing has been confirmed as asthma, with other causes such as throat infections, airway abno...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06851715 · University Hospital Southampton NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇬🇧 GB

Who might be able to join this trial: - Teenagers between 12 and 18 years old. - Those who attend a children's respiratory (breathing) clinic. - Those who have provided the appropriate consent — teenagers aged 16 and over can consent for themselves, while those aged 16 and under need both their own agreement and consen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06852911 · Novlead Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2025
🇨🇳 CN

**Who might be able to join this trial:** *For people with asthma:* - You must be at least 18 years old (any gender) - You must have been formally diagnosed with bronchial asthma according to recognised international guidelines (GINA 2023) - You must have been experiencing breathing-related symptoms for at least 6 wee...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06862206 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You must be at least 12 years old at the time of signing the consent form - You have been diagnosed with severe eosinophilic asthma and your doctor has decided to prescribe you a medication called benralizumab - Your blood test results show a high level of a type of white blo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06878352 · Federal University of Paraíba Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇧🇷 BR

Who might be able to join this trial: - You have been diagnosed with asthma by a doctor - You are receiving care or support from a Pulmonary Function Clinic (a clinic that specialises in breathing and lung health) - You have had a breathing test called spirometry that has shown some kind of breathing difficulty or abno...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06902766 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇫🇷 FR

**Who might be able to join this trial:** - Your child is between 4 and 12 years old and has been diagnosed with asthma by a doctor. - Your child is already being seen regularly for their asthma by a paediatrician or lung specialist for children. - Your child's asthma falls into a moderate or more serious category, acc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06903780 · Royal Devon and Exeter NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2025
🇬🇧 GB

**Who might be able to join this trial:** - People who have been receiving a biologic treatment for at least 6 months, but no longer than 18 months. - People who have not responded well to their biologic treatment (the trial is designed to include people in this situation, as doctors typically assess whether a biologic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06932263 · AstraZeneca Phase 2 · 21 countries Recruiting
Recruiting Phase 2 Est. completion 7 June 2027
🇦🇷 AR🇧🇷 BR🇨🇱 CL🇨🇳 CN🇫🇷 FR🇬🇷 GR🇭🇺 HU🇮🇳 IN +13 more

Who might be able to join this trial: - People who have signed and dated a written consent form before any study procedures begin. - Adults between 18 and 75 years of age at the time of signing the consent form. - People who have had a formal asthma diagnosis from a doctor for at least 12 months. - People who are curre...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06935084 · Montefiore Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇺🇸 US

Who might be able to join this trial: - People who speak English - People who have been diagnosed with persistent asthma by a healthcare provider and are currently taking a daily controller medication for it - People who are able to give informed consent to participate in the study - People who have access to a smartph...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06951867 · AstraZeneca Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 31 May 2029
🇩🇰 DK🇫🇷 FR🇩🇪 DE🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with asthma and are receiving a medicine called tezepelumab, or who are receiving high-intensity standard treatment for severe asthma, at some point during the study period. **Who may not be able to join:** - People who do not have at least 1...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06970080 · McMaster University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 June 2028
🇨🇦 CA

**Who might be able to join this trial:** - People who are able and willing to sign a written consent form agreeing to take part. - People who are able and willing to follow the study plan and attend required visits. - People aged 18 or older (male or female). - People who have been diagnosed with asthma by a lung spe...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06977581 · Pfizer Phase 2 · 15 countries Recruiting
Recruiting Phase 2 Est. completion 8 March 2027
🇦🇷 AR🇧🇪 BE🇧🇬 BG🇨🇳 CN🇨🇿 CZ🇭🇺 HU🇮🇹 IT🇯🇵 JP +7 more

**Who might be able to join this trial:** - You have had moderate-to-severe asthma that has persisted for at least 12 months before the screening appointment. - You have had at least one asthma flare-up in the past 12 months that required treatment with steroid tablets or injections for 3 or more days. - Your breathin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06981169 · Université de Sherbrooke Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇦 CA

Who might be able to join this trial: - People aged 6 years or older - People who have been referred by a primary care doctor for an asthma diagnostic test (such as a breathing test called spirometry or a methacholine challenge test) Who may not be able to join: - People who have been referred by a lung specialist (pu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07011524 · Keymed Biosciences Co.Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 21 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand the study procedures and are willing to sign a consent form agreeing to take part. - People aged 18 to 75 years old. - People with a body mass index (BMI) of 18.0 or higher (a measure of body weight relative to height). - People who have been...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07015749 · The First Affiliated Hospital of Soochow University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 20 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old (inclusive) - You weigh at least 40 kg (about 88 lbs) - You have been diagnosed with asthma for at least 12 months, confirmed by the study doctor - You have been on a stable inhaled asthma treatment (with or without inhaled steroids) for at...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07025200 · Medical University of Vienna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇦🇹 AT

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have a formal diagnosis of asthma recorded in their medical records - People whose asthma has been classified as severe, with specific blood and breathing test results showing high levels of inflammation markers (a breath...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07031102 · Helsinki University Central Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇫🇮 FI

**Who might be able to join this trial:** *For healthy children (control group):* - Children aged 7 to 15 years, of any sex - Children who have never been diagnosed with asthma - Children who have not used any inhaled asthma medication in the past 2 years - Children who have not experienced wheezing or shortness of br...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07037511 · University of British Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇨🇦 CA

**Who might be able to join this trial:** - Your aerobic fitness level (how well your body uses oxygen during exercise) must be above 120% of what is expected for someone your age and size (confirm with trial site) - Your Body Mass Index (BMI) must be between 18 and 30, which is a measure based on your height and weigh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07047430 · University of Washington Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

Who might be able to join this trial: - The child is between 6 and 12 years old and has been diagnosed with asthma by a healthcare provider. - The caregiver looking after the child is comfortable taking part in all study activities in English, including phone calls with study staff and completing online surveys. - The...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07052942 · DARTNet Institute Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 15 November 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with asthma for at least one year - People aged 13 to 75 years old - People who have been prescribed an inhaled corticosteroid (a type of asthma preventer inhaler), whether used regularly or on a scheduled as-needed basis — this includes inhale...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07059767 · Ethris GmbH Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇬🇧 GB

**Who might be able to join this trial:** - You must be able to understand and sign a consent form agreeing to follow the trial's rules and requirements. - You must be between 18 and 65 years old at the time you give your consent. - You must have a confirmed diagnosis of asthma, shown by specific breathing tests (conf...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07060079 · University College, London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2026
🇬🇧 GB

Who might be able to join this trial: - Adults aged 18 or older who have a long-term breathing or lung condition, with or without a sleep-related breathing disorder - People who have previously had sleep studies with negative results, who may be included as a comparison group - People who are able to read, understand,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07098403 · Guangdong Hengrui Pharmaceutical Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older. - A doctor has officially diagnosed you with asthma at least 12 months ago. - You have been taking a medium or high dose of inhaled asthma controller medication (called ICS) for at least 6 months. - You have been on a medium or high dose of this...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07103512 · Riphah International University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇵🇰 PK

Who might be able to join this trial: - People who have been diagnosed with allergic asthma - Both men and women are eligible to participate - People between the ages of 20 and 44 years old Who may not be able to join: - People who do not give their consent to take part in the trial - People who have other ongoing hea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07110116 · Riphah International University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
🇵🇰 PK

**Who might be able to join this trial:** - You are a man or woman between 18 and 60 years old who has been diagnosed with asthma - Your asthma is considered mild to moderate, based on a breathing test result showing your lungs are working at 60–80% of the expected level for someone your age and size - Your asthma has...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07116460 · Columbia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
🇺🇸 US

Who might be able to join this trial: - Children and teenagers between 7 and 18 years old - People who have had asthma symptoms in the past 4 weeks - People living in lower-income housing in Northern Manhattan or the South Bronx area of New York City Who may not be able to join: - People who are unable to complete the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07136025 · Beijing Chao Yang Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2029
🇨🇳 CN

Who might be able to join this trial: - People aged 18 years or older, but under 80 years old, who have been diagnosed with asthma for at least 6 months - People whose asthma is classified as severe under the 2024 GINA guidelines, meaning asthma that remains uncontrolled — with frequent symptoms or flare-ups — even whi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07137923 · Children's Hospital of Philadelphia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2027
🇺🇸 US

Who might be able to join this trial: - Children and teenagers between the ages of 5 and 18 years old - People who have had at least one clinic visit (for any reason — illness, a routine check-up, or a follow-up appointment) at one of the participating clinics during the study period - People who have been prescribed a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07138027 · Children's Hospital of Philadelphia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2027
🇺🇸 US

Who might be able to join this trial: - Children and teenagers between 5 and 18 years old - People who have had at least one clinic visit (for any reason — illness, a routine check-up, or a follow-up) at a participating clinic during the study period - People who have been prescribed at least one inhaled preventer medi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07139899 · Bastiaan Driehuys Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to give written consent to participate in the study - You are between 18 and 65 years old - A doctor has diagnosed you with asthma for more than 1 year - You have had breathing tests (lung function tests) done within the last 30 days that met standard...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07145632 · Karolinska Institutet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇸🇪 SE

Who might be able to join this trial: - You are older than 16 years of age - You are willing to take part voluntarily and able to give consent electronically using BankID or a similar service - You have been diagnosed with asthma or COPD by a doctor and use an inhaler (either a dry powder inhaler and/or a pressurised m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07161271 · Hong Kong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
Hong Kong

Who might be able to join this trial: - People who were supported with a type of lung support treatment called ECCO2R (a machine that helps remove carbon dioxide from the blood) at one of the study hospitals - People who were admitted to an intensive care unit (ICU) between 1 January 2022 and 30 June 2024 Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07166939 · Massachusetts General Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You are having an acute (sudden) asthma attack - You are between 18 and 54 years old - You speak English and/or Spanish - The emergency department doctor has decided you can go home with a short course of steroid pills or liquid - You are willing to use a specific rescue inha...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07168473 · Daewon Pharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 August 2026
🇰🇷 KR

**Who might be able to join this trial:** - Adults aged 19 years or older (male or female) - People who have a confirmed history or treatment record of year-round allergic rhinitis (such as allergies to dust mites or pet dander) for at least 2 years before the screening visit - People who have had a positive allergy t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07189806 · Hvivo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 August 2050
🇬🇧 GB

**Who might be able to join this trial:** - People aged 18 or older, of any gender, who have signed a consent form agreeing to take part. - People who attend the hVIVO respiratory clinic and have been diagnosed with asthma, confirmed by at least one of the following: a positive methacholine challenge test, a positive...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07196436 · The University of Texas at Arlington Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with asthma by a doctor, including adults and children between the ages of 5 and 17 - People who own their home and live in the Dallas-Fort Worth (DFW) metropolitan area in Texas Who may not be able to join: - People who live in a home where anyone...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07214753 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇮🇹 IT

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with severe eosinophilic asthma that is not well controlled. - People for whom a doctor has prescribed the medication benralizumab in line with its approved use and local funding or coverage requirements. - People who have signed a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07224061 · Montefiore Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2031
🇺🇸 US

**Who might be able to join this trial:** - Your child has been diagnosed with asthma by a doctor, and this is recorded in their medical records. - Your child has persistent or poorly controlled asthma, meaning at least one of the following applies in the past month: symptoms on more than 2 days per week, using a quick...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07228026 · Biometry Inc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇺🇸 US

Who might be able to join this trial: **Uncontrolled Asthma Group** - People aged 5 years or older, male or female - People (or their legal guardian, if under 18) who have read, understood, and signed the consent forms for the study - People who have been diagnosed with asthma - People who are willing and able to comp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07228052 · Montefiore Medical Center Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who came to the emergency department (ED) because of an asthma attack - People who have been diagnosed with asthma, either through official medical classification or by the doctor treating them at the time - People who were sent home from the ED with a...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07241117 · Washington University School of Medicine Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 15 November 2027
🇺🇸 US

**Who might be able to join this trial:** **Clinics:** - The clinic must be an active participant in the St. Louis Integrated Health Center Network for Community Academic Partnerships. - The clinic must employ at least 3 clinicians who regularly manage adult asthma patients (meaning they see at least one adult asthma...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07241546 · Arrowhead Pharmaceuticals Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇦 CA

Who might be able to join this trial: - People who have mild asthma that is currently stable, with lung function measured at 70% or more of what is expected for someone of their age and size - People who have a confirmed allergy, shown by a positive skin prick test done at the start of the study - People who are able a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07261423 · University of Pittsburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇺🇸 US

Who might be able to join this trial: - People aged 8 to 17 years old - People who have been diagnosed by a healthcare provider with persistent asthma (moderate to severe levels) or mild intermittent asthma that has led to at least one serious asthma attack in the past 12 months — where a serious attack means needing s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07276724 · Generate Biomedicines Phase 3 · 6 countries Recruiting
Recruiting Phase 3 Est. completion 1 December 2028
🇧🇬 BG🇩🇪 DE🇭🇺 HU🇱🇻 LV🇷🇴 RO🇺🇸 US

**Who might be able to join this trial:** - People aged 12 to 80 years old. - People who have had a confirmed asthma diagnosis from a doctor for at least 2 years. - People who have been taking a medium-to-high dose inhaled corticosteroid (a type of inhaled asthma preventer) for at least 12 months, plus at least one ot...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07280364 · I.M. Sechenov First Moscow State Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇷🇺 RU

Who might be able to join this trial: - People aged between 12 and 17 years old - People who have been officially diagnosed with asthma - People who have given their voluntary, informed agreement to take part in the study Who may not be able to join: - People who are under 12 years of age - People who do not have a co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07282886 · University of Alabama at Birmingham Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇺🇸 US

Who might be able to join this trial: - People aged 18 to 75 years old - People with a confirmed asthma diagnosis, with a documented history of asthma for at least 1 year, where the diagnosis was made before age 40, and/or whose lung function test results fall within a specific range (confirm with trial site) - People...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07292805 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2029
🇳🇱 NL

**Who might be able to join this trial:** - People who are over 18 years old - People who have severe asthma that is not well controlled (based on a specific asthma control score called the ACQ being above 1.5), even after trying the highest recommended level of asthma treatment - People who have already tried at leas...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07301255 · Enveda Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are able to read, understand, and sign a consent form before any study activities begin - Adults between 18 and 75 years old who have been diagnosed by a doctor with moderate to severe asthma for at least 12 months - People whose asthma treatment has been stable o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07301736 · Chiesi Farmaceutici S.p.A. Phase 2 · 14 countries Recruiting
Recruiting Phase 2 Est. completion 3 June 2027
🇦🇷 AR Bosnia and Herzegovina🇧🇬 BG🇨🇿 CZ🇩🇪 DE🇭🇺 HU🇱🇻 LV🇲🇽 MX +6 more

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) - You have been diagnosed with asthma for at least 6 months before the screening visit, and your asthma was first diagnosed before you turned 50 - You are a non-smoker or a former smoker - Your body weight is in a healthy range...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07313904 · First Affiliated Hospital of Ningbo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People between 18 and 80 years old (including those aged exactly 18 or 80); any gender or race may be considered - People with no history of asthma, allergic bronchopulmonary aspergillosis (a lung condition caused by mold allergy), or other long-term breathing conditions - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07320066 · Istanbul Esenyurt University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
Turkey (Türkiye)

**Who might be able to join this trial:** - People aged between 18 and 65 years old - People who have been formally diagnosed with severe, persistent, non-allergic asthma by a lung specialist, following recognised international guidelines - People whose test results show low levels of certain inflammation markers in t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07323654 · Kymera Therapeutics, Inc. Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇩🇪 DE🇵🇱 PL🇷🇴 RO🇷🇸 RS🇸🇰 SK🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 75 years old at the time of signing the consent form (or the legal age of consent in the country where the study is taking place, if that differs). - People who have been diagnosed with asthma by a doctor for at least 1 year before the screening visit. - Pe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07324707 · Anhui Palo Alto Pharmaceuticals, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (any gender) - You have been diagnosed with bronchial asthma — this includes a new diagnosis, or asthma first diagnosed in childhood or teenage years that has become more noticeable or worse in adulthood - Breathing tests before joining th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07326995 · Anhui Palo Alto Pharmaceuticals, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any gender - People who have been diagnosed with bronchial asthma according to Chinese clinical guidelines — including those newly diagnosed, or those diagnosed with asthma during childhood or adolescence whose symptoms have become noticeably w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07328035 · Thammasat University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇹🇭 TH

Who might be able to join this trial: - People who have been diagnosed with severe asthma - People who are 18 years of age or older Who may not be able to join: - People who are unable to perform a breathing test called spirometry (where a person blows into a device to measure lung function) - People who are unable to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07330778 · Celldex Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2027
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older (any gender) - You have been diagnosed with mild to moderate asthma for at least 12 months - Your lung function (measured by a breathing test) is at or above 70% of the expected normal level before using an inhaler - Your airways show a meaningful...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07342803 · Longbio Pharma Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 to 75 years, of any gender, who weigh at least 40 kg (approximately 88 lbs) - People who have been diagnosed with bronchial asthma for at least 1 year, and who have also been diagnosed with allergic asthma - People who have had at least one asthma flare-up in...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07348302 · Inmunotek S.L. Phase 3 · 4 countries Recruiting
Recruiting Phase 3 Est. completion 27 April 2029
🇦🇷 AR🇨🇳 CN🇵🇹 PT🇪🇸 ES

**Who might be able to join this trial:** - People who have signed and dated a consent form agreeing to take part in the trial. - People aged 12 to 65 years old at the time of signing the consent form (both ages included). - People who have had a confirmed history of allergy to something inhaled — specifically house d...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07351916 · Thammasat University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇹🇭 TH

"Who might be able to join this trial: - People who have been diagnosed with mild-to-moderate asthma - People who are 18 years of age or older Who may not be able to join: - People who are unable to complete breathing tests, specifically a lung function test (called spirometry) and a breath test that measures airway i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07359846 · Generate Biomedicines Phase 3 · 6 countries Recruiting
Recruiting Phase 3 Est. completion 1 January 2029
🇦🇷 AR🇧🇪 BE🇯🇵 JP🇷🇸 RS🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People aged 12 to 80 years old. - People who have had a formal diagnosis of asthma from a doctor for at least 2 years. - People who have been taking a medium-to-high dose inhaled corticosteroid (a type of preventer inhaler) for at least 12 months, plus at least one other ast...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07363642 · AstraZeneca Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 7 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to give written agreement to take part before any study procedures begin. - People aged 12 to 80 years old at the first study visit. - People who have a formal diagnosis of asthma from a doctor, confirmed by medical records. - People whose bre...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07372287 · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who understand the study and are willing to sign a consent form agreeing to take part - People aged 18 to 80 years old (male or female) who weigh at least 40 kg - People who have been diagnosed with asthma for at least one year - People whose lung function test result...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07381790 · Helse Møre og Romsdal HF Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2029
🇳🇴 NO

Who might be able to join this trial: - People who have been diagnosed with a lower respiratory tract infection (an infection affecting the lungs or airways) - People who are breathing faster than normal (tachypnea) - People who have a wheezing sound when breathing - People who are showing visible effort when breathing...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07383883 · Shanghai Children's Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2028
🇨🇳 CN

Who might be able to join this trial: - Children between the ages of 5 and 18 years old - Children who have been diagnosed with asthma based on established medical guidelines for childhood asthma - Children who are already attending regular outpatient appointments at Shanghai Children's Medical Center - Children who ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07402200 · University Hospital, Montpellier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇫🇷 FR

**Who might be able to join this trial:** - Your child is already taking part in the SynAir-G observational study - Both the child and their parent(s) or guardian(s) are willing to follow the study procedures - The child's parent(s) or guardian(s) are able to give written consent for the child to take part - **For the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07402707 · Sheffield Children's NHS Foundation Trust Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 August 2026
🇬🇧 GB

**Who might be able to join this trial:** - Children between 4 and 15 years old (inclusive) who come to the emergency department with an asthma attack, where treatment guidelines recommend oral steroids as part of their care. - Children whose parents or carers speak Slovakian, Arabic, or Urdu (rather than English) may...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07412769 · Meyer Children's Hospital IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇮🇹 IT

Who might be able to join this trial: - Children and teenagers between 6 and 17 years old - People who have come to an emergency department with an acute asthma attack - People who are being seen at one of the emergency departments taking part in this study, during the study period Who may not be able to join: - Child...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07425639 · Celltrion HealthCare France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇫🇷 FR

Who might be able to join this trial: - You are 18 years old or older and are receiving specialist care for either severe asthma or chronic spontaneous urticaria (a long-term skin condition causing hives). - You have been treated with the medication omalizumab (the original/reference version) for at least 6 months for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07426458 · University of Miami Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 April 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with asthma by a doctor - People whose lungs are working at less than 80% of the expected level, and whose breathing improves by at least 10% after using a reliever inhaler during a breathing test - Adults between 18 and 75 years of age - People who...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07431021 · Queen Mary University of London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇬🇧 GB

Who might be able to join this trial: - Children who attend schools in Central and East London that have been recruited to take part in this study Who may not be able to join: - Children who are unable to safely take part in physical education (PE) lessons, as reported by their parents - Children whose learning or phy...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07431580 · Mona Lichtblau Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇨🇭 CH

**Who might be able to join this trial:** - People who have been diagnosed with asthma that is well controlled - People aged between 18 and 80 years old - People of any sex or gender - People who currently live below 800 metres in altitude and have not spent more than 24 hours at an altitude above 2,500 metres in the p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07447596 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 July 2026
🇪🇸 ES

Who might be able to join this trial: - Adults aged between 18 and 90 years old - People who have had a breathing test called spirometry performed (results must be available) - People who have been diagnosed by a doctor with a chronic lung condition — specifically COPD, asthma, or interstitial lung disease — based on r...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07452380 · The Children's Hospital of Zhejiang University School of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are between 5 and 17 years old (inclusive) - You have been diagnosed with allergic rhinitis (hay fever-like symptoms) caused by dust mites (specifically *Dermatophagoides pteronyssinus* and/or *Dermatophagoides farinae*), or a blood test has shown a significant allergic r...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07453667 · Case Western Reserve University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - At least one child under 18 years old living in the home must have a confirmed diagnosis of asthma. - A parent or guardian must be able to read and sign a consent form to participate in the study. - The home must be located within the City of Cleveland or in nearby areas such as...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07456033 · GlaxoSmithKline Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 8 July 2030
🇺🇸 US

**Who might be able to join this trial:** - People aged 12 or older at the time of signing the consent form (in some countries, only adults aged 18 or older may be eligible, depending on local rules). - People who have had a formal asthma diagnosis from a doctor for at least 2 years, confirmed according to recognised...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07480616 · RSUP Persahabatan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇮🇩 ID

Who might be able to join this trial: - People who have been diagnosed with stable asthma - People who are between 18 and 65 years old - People who are mentally capable of making decisions and are willing to take part in the trial Who may not be able to join: - People who are currently experiencing a worsening or flar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07486401 · National Healthcare Group Polyclinics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇸🇬 SG

**Who might be able to join this trial:** - People who are Singaporean citizens or Singapore Permanent Residents - People aged 21 to 65 years old - People who have been diagnosed with asthma by a doctor for at least 4 weeks - People who are on, or are about to start, a mild-to-moderate level of asthma treatment (known...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07489911 · Chiesi Slovenija, d.o.o. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇸🇮 SI

Who might be able to join this trial: - People who have been formally diagnosed with asthma by a doctor (following established international guidelines) and have been receiving treatment for asthma for at least 3 years before joining the study - Adults aged 18 or older who are receiving outpatient care (not currently a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07493629 · First Affiliated Hospital of Ningbo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇨🇳 CN

Who might be able to join this trial: - You must be at least 18 years old (or at least 40 years old if you have COPD) - You have been diagnosed with one of the following conditions: asthma, a fungal-related lung condition called ABPA, bronchiectasis, sleep apnea (OSAS), or COPD - You have a specific breathing pattern o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07500246 · Luxembourg Institute of Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇱🇺 LU

Who might be able to join this trial: - Children between 5 and 16 years old, either male or female - Children who have been diagnosed with asthma by a doctor and need regular asthma medication (inhaled corticosteroids, with or without a long-acting reliever) taken through a metered-dose inhaler - Children whose asthma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07508280 · Riphah International University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇵🇰 PK

Who might be able to join this trial: - People who have been diagnosed with asthma and have a lung function measurement (called FEV) falling between 60% and 80% of the expected value Who may not be able to join: - People who are pregnant - People who have previously received breathing exercise training - People who ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07516184 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 June 2027
🇨🇳 CN

Who might be able to join this trial: - People who are between 18 and 75 years old at the time of joining the trial - People who have experienced asthma-like symptoms — such as wheezing, shortness of breath, chest tightness, or coughing — for at least 2 months before joining, whether or not they have been formally diag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07525375 · AstraZeneca Phase 2 · 7 countries Recruiting
Recruiting Phase 2 Est. completion 23 May 2029
🇦🇷 AR🇨🇿 CZ🇭🇺 HU🇲🇽 MX🇵🇱 PL🇷🇸 RS🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed diagnosis of asthma that was made by a doctor. - People who have been regularly and consistently using an inhaled corticosteroid (a type of preventer inhaler) plus one other asthma controller medication. - People whose Childhood Asthma Control Tes...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07529847 · Foundation University Islamabad Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 May 2026
🇵🇰 PK

Who might be able to join this trial: - People who are between 18 and 45 years old - Both men and women are eligible - People who experience breathlessness rated at Grade 1 to 3 on a standard breathlessness scale called the mMRC (this measures how much shortness of breath affects daily activities) - People with asthma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07530770 · Qianfoshan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years old (inclusive) who have been diagnosed by a doctor with Allergic Bronchopulmonary Aspergillosis (ABPA), a lung condition caused by an allergic reaction to a type of mould called Aspergillus - People whose ABPA diagnosis meets specific diagnost...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07546981 · Chiesi Farmaceutici S.p.A. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 17 October 2028
🇨🇳 CN

Who might be able to join this trial: - People who are willing and able to provide written consent before any study procedures begin - People who are Chinese, male or female, and between 18 and 75 years of age - People who have a documented asthma diagnosis of at least 1 year, and whose asthma was first diagnosed befor...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07556159 · Sanofi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 April 2029
🇺🇸 US

**Who might be able to join this trial:** **For Part 1 of the trial:** - You are 6 years old or older at the time of signing the consent form - A doctor has diagnosed you with asthma at least 12 months ago - You are already using an inhaled steroid (low, medium, or high dose) along with other asthma medicines as part...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07589439 · Shanghai Novamab Biopharmaceuticals Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 12 to 75 years, male or female, who are being treated as outpatients, with a body mass index (BMI) between 18 and 30, and — for those aged 12 to 17 — a body weight of at least 30 kg. - People who have been diagnosed with asthma according to 2025 international ast...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07610447 · Bezmialem Vakif University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 May 2027
Turkey (Türkiye)

**Who might be able to join this trial:** - Children and teenagers between the ages of 10 and 17 years old - People who have been diagnosed with asthma by a doctor, based on recognised international asthma guidelines - People whose asthma treatment has been stable and unchanged for a period of time - People who are phy...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07620691 · University of Saskatchewan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇨🇦 CA

Who might be able to join this trial: - People who play golf regularly, meaning two or more times per week Who may not be able to join: - People who currently smoke Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07632352 · Henan University of Traditional Chinese Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 September 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with an acute flare-up (worsening) of bronchial asthma, based on standard Western medical diagnosis - People who are 18 years of age or older - People who agree to take part willingly and sign a consent form before joining Who may not be able to jo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07653347 · University of British Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇦 CA

Who might be able to join this trial: - Pairs consisting of a birthing parent and their newborn child, where the birth took place or is planned to take place in April, May, June, September, October, or November at BC Women's Hospital + Health Centre or a nearby local hospital. Who may not be able to join: - Pairs wher...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07655037 · Helsinki University Central Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇫🇮 FI

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed by a doctor with severe asthma (using standard medical guidelines called GINA criteria) and for whom a doctor has decided to start a biological medication — specifically one of: omalizumab, mepolizumab, benralizumab,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07660731 · Pfizer Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 18 June 2027
🇺🇸 US

Who might be able to join this trial: - You are male, or female and no longer able to have children - You are between 18 and 65 years old - Your body mass index (BMI) is between 16 and 32, and you weigh more than 50 kilograms (110 pounds) - For one specific optional group (Part A, Japanese participants only): you weigh...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07665892 · Aspeya, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 55 years old - People who have been diagnosed with asthma - People whose asthma treatment has been stable (not recently changed) - People who do not smoke - People whose body weight falls within a healthy range for their height (a BMI between 18.5 and 35...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07677059 · Kymera Therapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People who completed all required visits in the earlier ("parent") study, up to and including the final treatment visit. - People who are willing and able to attend scheduled appointments, follow the treatment plan, complete lab tests, answer questionnaires, and keep an elect...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Asthma. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Asthma Australia provides direct support for people with asthma. The National Asthma Council Australia, a collaboration of medical societies, sets the clinical guidelines and professional education standards.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.